Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANTHER: Etrumadenant and Zimberelimab with Chemoradiation for Rectal Cancer
NCT05024097Phase 2Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of etrumadenant, zimberelimab in rectal cancer, sponsored by Weill Cornell Medicine. Started Mar 2022; status: recruiting.
02
Drugs
etrumadenantzimberelimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05024097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024097.